William Blair cuts Moderna to market perform from outperform
MRNA•William Blair cut its rating on Moderna to market perform from outperform.
Related News
SunCoke Energy expects 2026 adjusted EBITDA to modestly exceed $265 million guidance high end
SXC•
Caris Life Sciences target price raised to $38 from $33
CAI•
Terrestrial Energy authorizes share repurchase program up to $25 million
IMSR•
Greek bank financing growth slows to 2.4% in September, Bank of Greece says
SPY•
Guidewire signs definitive agreement to acquire Hyperexponential
GWRE•